RxDoctor Payments Data

Ashok Patel, MD

Psychiatry · Largo, FLNPI 1124091798

Payments from drug & device makers

$301,127in general payments, 2019–2025

Across 386 payments — averaging $780.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka Pharmaceutical Development & Commercialization, Inc.$173K
  • Roche TCRC, Inc.$35K
  • Livanova USA, Inc.$28K
  • Avanir Pharmaceuticals, Inc.$27K
  • GW Research Limited$26K
  • Jazz Pharmaceuticals Inc.$3K
  • plus $10K from 29 others

What the payments were for

  • Speaking & faculty fees$5007%
  • Food & beverage$6,51493%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$301,127 in reported general payments places this provider in the 95th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$151,874
Medicare patients
244
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate16$130,431
RexultiBrexpiprazole54$78,081
VraylarCariprazine Hcl49$75,090
Wellbutrin XlBupropion Hcl12$68,506
TrintellixVortioxetine Hydrobromide73$43,659
Invega SustennaPaliperidone Palmitate15$42,294
Aripiprazole541$39,802
NeurontinGabapentin12$16,904
Lurasidone Hcl72$15,656
Quetiapine Fumarate827$13,950
BelsomraSuvorexant23$9,753
Oxcarbazepine220$8,855
Buspirone Hcl601$8,503
Bupropion XlBupropion Hcl525$7,865
Trazodone Hcl907$7,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$504$130,43116 claims
Otsuka America Pharmaceutical, Inc.Rexulti$455$78,08154 claims
AbbVieVraylar$1,328$75,09049 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$276$50,34891 claims
Johnson & JohnsonInvega Sustenna$215$42,29415 claims
MerckBelsomra$44$9,75323 claims
Almatica Pharma LLCSertraline Hcl$111$3,415535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →